Sorin Gains Distribution Rights, Minority Stake In Respicardia’s remedē Sleep Apnea Device
This article was originally published in The Gray Sheet
Sorin’s $20 million investment will help Respicardia continue the U.S. pivotal trial of the remedē implantable phrenic nerve stimulator for sleep apnea and give Sorin exclusive rights to distribute the device in select European countries, where it has a CE mark but has yet to be launched.
You may also be interested in...
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions over the past month. This edition takes a closer look at Respicardia, which has cut short the post-approval study of its implantable sleep apnea device study.
The implantable neurostimulation system works automatically and continuously during every hour of sleep and does not depend on patient adherence, which has been a major limitation of continuous positive airway pressure therapy.
New prosthetic leg can receive signals from the patient’s nervous system to improve control. Study shows repeated bone-mineral density tests do not improve the prediction of osteoporosis-related injury.